to a unique
combination
of IG + Hy

IG=Immune Globulin
Hy=Hyaluronidase

Where IG meets Hy

HyQvia is an IG + Hy CIDP maintenance therapy for adults that is given subcutaneously.
But it’s different from traditional IVIG and SCIG therapies because it’s made with a unique
component: hyaluronidase, or Hy.

HyQvia is the only
IG therapy that combines IG with Hy

IG icon.

The IG in HyQvia is thought to
reduce damage to the nerves and
assist in defending the nerves from
harm. The IG component of HyQvia
is similar to the IG in IVIG therapies.

Plus sign icon.
Hy icon.

Hy helps your body take in and disperse a
larger amount of IG, which is why HyQvia
can be infused up to monthly.*

*Every 2, 3, or 4 weeks.

Infusion icon.

Experts agree: IG is a
standard of care in CIDP and
is recommended as
maintenance therapy.

The current EAN/PNS consensus
guideline recommends IVIG or

SCIG as maintenance therapy in

IVIG-responsive patients with CIDP.

How does Hy work?

Infusion needle inserted in fatty tissue directly beneath the skin, filled with hyaluronan graphic.

Your body naturally contains hyaluronan

The fatty tissue directly beneath your skin is naturally filled with a substance called hyaluronan.

Absence of Recombinant Human Hyaluronidase (Hy) graphic.

Hyaluronan limits
the volume of IG
you can infuse

Without the Hy in HyQvia, hyaluronan would limit the amount of IG that can be infused into the fatty tissue.

IG to reaching subQ tissue graphic.

Hy makes room
for a larger volume
of IG

Hy allows a larger amount of IG to reach the fatty tissue and be absorbed into the bloodstream.

Can relapses be prevented?

With CIDP, you may experience a range of symptoms, including muscle weakness in the arms and legs. Even after treatment with improvement, these symptoms can still occur—this is called a relapse.

HyQvia is a CIDP maintenance therapy that helps prevent relapses in adult patients

That means once you get your symptoms under control with stable doses of IVIG,
your doctor may prescribe a maintenance therapy like HyQvia to help prevent relapse.
In a 6-month clinical trial, relapse rates were different for people receiving HyQvia (14.0%)
vs placebo (32.3%).

In a 6-month clinical trial*

People experiencing relapse graphic.

Darker icon figures in graphic indicate patients who experienced a relapse.

*57 patients received HyQvia, and 65 patients received placebo.

A majority of patients in the trial infused every 4 weeks, in ~2 hours and with 2 infusion sites.

HyQvia provided superior relapse prevention.

Yep, we said superior. In a study, HyQvia demonstrated superior relapse prevention over
placebo for patients who transitioned from IVIG.

Ask your doctor for more information about HyQvia study data to see how it may impact your treatment decision.

What are the common side effects of HyQvia?

Side effects icon.
  • Overall, the most common side effects are headache (reported in 3
    out of every 100 infusions), fatigue, nausea, fever, itching, redness,
    abdominal pain, back pain, and pain in extremity
  • Local side effects, meaning they occur around the infusion site, are
    common. This could be mild to moderate pain, redness, swelling,
    and itching. In the clinical study, ~75% of patients did not report
    local side effects
  • These are not all the possible side effects for HyQvia. Talk to your
    healthcare professional about any side effects that bother you or that
    don’t go away

Please see additional Important Safety Information below,
including Warning about Blood Clots.

CIDP=chronic inflammatory demyelinating polyneuropathy; EAN=European Academy of
Neurology; IVIG=intravenous immune globulin; PNS=Peripheral Nerve Society;
SCIG=subcutaneous immune globulin.

Ready to talk to your doctor?

Great. We’ve got just the support for you. Our Doctor Discussion Guide can help you get organized and ready for your conversation with your doctor.